Treasury Yields Set to Stay High as Debt Supply Pressures Bond Market 
Australia GDP Beats Forecast, Boosting RBA Rate Hike Bets 
Oil Prices Rise as U.S.-Iran Fighting Fuels Supply Fears 
Australia Current Account Deficit Widens to A$27.2 Billion 
India Manufacturing Growth Slows to Five-Year Low in August 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Canada Backs €100 Billion Global Defence Bank 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Dollar Hits Two-Week High as Iran Conflict Lifts Oil and Bond Yields 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Ukraine Sanctions Chief Heads to Washington to Push Russia Bill 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
